

FOI REF: 25/826

28th November 2025

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

I am conducting analysis on the treatment of breast cancer in secondary care and kindly request your help.

I would be grateful if you could answer the questions below in relation to the number of patients treated with specific medicines between the start of July 2025 to the end of September 2025, or the latest three-month period for which data is available. Please include data for all hospitals in the Trust.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	53
1.2 Alpelisib (Piqray)	2
1.3 Elacestrant (Orserdu)	2
1.4 Fulvestrant (fulvestrant or Faslodex)	32
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	68
1.7 Ribociclib (Kisqali)	30
1.8 Capivasertib (Truqap)	1
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	18

Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	46
2.2 Ribociclib (Kisqali)	4
2.3 Olaparib (Lynparza)	0

Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	8
3.2 Ribociclib (Kisqali)	7

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	0
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	5
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	24

Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of July 2025 and the end of September 2025?

Type of breast cancer	Number patients treated
5.1 Olaparib - All types of breast cancer	0
5.2 Olaparib - Locally advanced or metastatic breast cancer	0
5.3 Talazoparib – All types of breast cancer	0

Q6. How many patients were treated in total with the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	0
6.2 Pertuzumab with Trastuzumab (Phesgo)	1
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	56
6.4 Trastuzumab Deruxtecan (EnHertu)	0
6.5 Trastuzumab Emtansine (Kadcyla)	12
6.6 Tucatinib (Tukysa)	0
6.7 Neratinib (Nerlynx)	0

Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	56
7.2 Trastuzumab Deruxtecan (EnHertu)	0

Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Products	Number patients treated
8.1 Pertuzumab (Perjeta)	0
8.2 Pertuzumab with Trastuzumab (Phesgo)	0
8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	24
8.4 Trastuzumab Emtansine (Kadcyla)	5

Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Products	Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
9.1 Pertuzumab (Perjeta)	0	0	0
9.2 Pertuzumab with Trastuzumab (Phesgo)	0	1	1
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	47	9	56
9.4 Trastuzumab Emtansine (Kadcyla)	7	5	12

Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
10.1 HER2+ve Breast Cancer	0
10.2 HER2-low Breast Cancer	0

Q11. How many patients were treated for the following indications for metastatic HER2+ve breast cancer by product, in the 3 months between 1st July 2025 and 30th September 2025, or latest 3-months for which data are available?

Name of medicine	Line of Therapy (indication)	Number patients treated
11.1 Trastuzumab Deruxtecan (Enhertu)	Following one or more prior anti-HER2-based regimens	0
11.2 Trastuzumab Deruxtecan (Enhertu)	Following one prior anti HER2-based regimen	0
11.3 Trastuzumab Emtansine (Kadcyla)	Following one or more prior anti-HER2-based regimens	6
11.4 Trastuzumab Emtansine (Kadcyla)	Following one prior anti HER2-based regimen	6
11.5 Trastuzumab	Following one or more prior anti-HER2-based regimens	5
11.6 Trastuzumab	Following one prior anti HER2-based regimen	4

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net